UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

Date of Report: June 23, 2017 Commission File Number: 001-36891

Cellectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry 75013 Paris, France +33 1 81 69 16 00 (Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F 🗹 Form 40-F 🗌

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit <u>Title</u>

r.

99.1 Press release, dated **June 23, 2017.**

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

June 23, 2017

CELLECTIS S.A.

(Registrant)

By: /s/ André Choulika

André Choulika Chief Executive Officer

3

Calyxt Files Registration Statement for Proposed Initial Public Offering

ST. PAUL, Minn. & NEW YORK--(BUSINESS WIRE)--June 23, 2017--Regulatory News:

Cellectis S.A. (Alternext : ALCLS ; Nasdaq : CLLS) and Calyxt, Inc. announced that Calyxt has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) of shares of Calyxt common stock. Calyxt is Cellectis' 100% owned gene editing agriculture company. The number of shares to be offered and the price range for the offering have not yet been determined, although Cellectis intends to retain majority ownership of Calyxt.

Citigroup, Credit Suisse and Jefferies are acting as joint book-running managers for the proposed offering. Wells Fargo Securities is acting as lead manager and Ladenburg Thalmann is acting as co-manager.

This offering will be made only by means of a prospectus (included in the registration statement on Form S-1). When available, a copy of the preliminary prospectus may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com; or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. The registration statement is available at <u>https://www.cellectis.com/FINAL.calyxt.s1.june.23.2017.pdf</u>. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

CONTACT: **Media** Jennifer Moore, VP Communications Phone: 917-580-1088 email: <u>media@calyxt.com</u> / <u>media@cellectis.com</u> or Caitlin Kasunich / Nick Opich KCSA Strategic Communications Phone: 212-896-1241 / 212-896-1206 email: <u>ckasunich@kcsa.com / nopich@kcsa.com</u> or **Investor Relations** Simon Harnest, VP Corporate Strategy and Finance

Simon Harnest, VP Corporate Strategy and Finance Phone: 646-385-9008 email: <u>simon.harnest@cellectis.com</u>